Actinium shares surge 11.18% intraday as new preclinical data highlight pan-tumor and AML treatment potential.

Actinium Pharmaceuticals surged 11.18% intraday following the announcement of two upcoming data presentations at the AACR 2026 Annual Meeting on April 21, showcasing preclinical advancements for ATNM-400 and Actimab-A. The presentations highlight ATNM-400’s broad pan-tumor activity across solid tumors and Actimab-A’s mutation-agnostic mechanism in acute myeloid leukemia, reinforcing the company’s Ac-225 radiotherapy platform as a potential differentiator in oncology. Management emphasized the platform’s versatility and value-creation potential, driving positive investor sentiment ahead of the data release.